Background:
Gut microbiota and its metabolites may be involved in the pathogenesis of inflammatory bowel disease. Several clinical studies have recently shown that patients with ulcerative colitis (UC) have altered profiles of fecal bile acids (BAs). It was observed that BA receptors Takeda G-protein-coupled receptor 5 (TGR5) and vitamin D receptor (VDR) participate in intestinal inflammatory responses by regulating NF-ĸB signaling. We hypothesized that altered profiles of fecal BAs might be correlated with gut microbiota and inflammatory responses in patients with UC.
Aim:
To investigate the changes in fecal BAs and analyze the relationship of BAs with gut microbiota and inflammation in patients with UC.
Methods:
The present study used 16S rDNA sequencing technology to detect the differences in the intestinal flora between UC patients and healthy controls (HCs). Fecal BAs were measured by targeted metabolomics approaches. Mucosal TGR5 and VDR expression was analyzed using immunohistochemistry, and serum inflammatory cytokine levels were detected by ELISA.
Results:
Thirty-two UC patients and twenty-three HCs were enrolled in this study. It was found that the diversity of gut microbiota in UC patients was reduced compared with that in HCs. , , , , , and were significantly decreased in patients with UC ( = 3.75E-05, = 8.28E-07, = 0.0002, = 0.003, = 0.0003, and = 0.0004, respectively). , , , , and were significantly enriched in the UC group ( = 2.99E-09, = 3.63E-05, = 8.59E-05, 0.003, and = 0.016, respectively). The concentrations of fecal secondary BAs, such as lithocholic acid, deoxycholic acid, glycodeoxycholic acid, glycolithocholic acid, and taurolithocholate, in UC patients were significantly lower than those in HCs ( = 8.1E-08, = 1.2E-07, = 3.5E-04, = 1.9E-03, and = 1.8E-02, respectively) and were positively correlated with , , , , and ( < 0.01). The concentrations of primary BAs, such as taurocholic acid, cholic acid, taurochenodeoxycholate, and glycochenodeoxycholate, in UC patients were significantly higher than those in HCs ( = 5.3E-03, = 4E-02, = 0.042, and = 0.045, respectively) and were positively related to , , , and pro-inflammatory cytokines ( < 0.01). The expression of TGR5 was significantly elevated in UC patients (0.019 ± 0.013 0.006 ± 0.003, 0.0003). VDR expression in colonic mucosal specimens was significantly decreased in UC patients (0.011 ± 0.007 0.016 ± 0.004, = 0.033).
Conclusion:
Fecal BA profiles are closely related to the gut microbiota and serum inflammatory cytokines. Dysregulation of the gut microbiota and altered constitution of fecal BAs may participate in regulating inflammatory responses the BA receptors TGR5 and VDR.
Citing Articles
The role of gut microbiota and plasma metabolites in ulcerative colitis: Insights from Mendelian randomization analysis.
Zheng X, Fan J, Yin J, Chu Y
Medicine (Baltimore). 2025; 104(9):e41710.
PMID: 40020117
PMC: 11875619.
DOI: 10.1097/MD.0000000000041710.
Dietary protein source mediates colitis pathogenesis through bacterial modulation of bile acids.
Gray S, Wood M, Mulkeen S, Ahmed S, Thaker S, Chen B
bioRxiv. 2025; .
PMID: 39896483
PMC: 11785241.
DOI: 10.1101/2025.01.24.634824.
Bile Acids in Inflammatory Bowel Disease: From Pathophysiology to Treatment.
Bai S, Chandnani A, Cao S
Biomedicines. 2025; 12(12).
PMID: 39767816
PMC: 11673883.
DOI: 10.3390/biomedicines12122910.
An Integrated Analysis of the Role of Gut Microbiome-Associated Metabolites in the Detection of MASH-Related Cirrhosis.
Xiong F, Zhang X, Jiang Y, Meng P, Zhou Y, Ji X
Metabolites. 2024; 14(12).
PMID: 39728462
PMC: 11678040.
DOI: 10.3390/metabo14120681.
Composition of Human-Associated Gut Microbiota Determines 3-DF and 3-HF Anti-Colitic Activity in IL-10 -/- Mice.
Haro-Reyes J, Raghupathi J, Reddivari L
Nutrients. 2024; 16(23).
PMID: 39683625
PMC: 11644234.
DOI: 10.3390/nu16234232.
External damp environment aggravates diarrhea in spleen deficiency and dampness syndrome in mice: involvement of small intestinal contents microbiota, energy metabolism, gastrointestinal and fluid functions.
Yu D, Xie S, Guo M, Wu Y, Tian Q, Wang Z
Front Cell Infect Microbiol. 2024; 14:1495311.
PMID: 39544280
PMC: 11560853.
DOI: 10.3389/fcimb.2024.1495311.
Insights into Gut Dysbiosis: Inflammatory Diseases, Obesity, and Restoration Approaches.
Acevedo-Roman A, Pagan-Zayas N, Velazquez-Rivera L, Torres-Ventura A, Godoy-Vitorino F
Int J Mol Sci. 2024; 25(17).
PMID: 39273662
PMC: 11396321.
DOI: 10.3390/ijms25179715.
Modeling "Two-Hit" Severe Pneumonia in Mice: Pathological Characteristics and Mechanistic Studies.
Zhao M, Wang B, Zhou F, Fang C, Zhu B, Zhou M
Inflammation. 2024; .
PMID: 39212889
DOI: 10.1007/s10753-024-02136-w.
The involvement of oral bacteria in inflammatory bowel disease.
Xiang B, Hu J, Zhang M, Zhi M
Gastroenterol Rep (Oxf). 2024; 12:goae076.
PMID: 39188957
PMC: 11346772.
DOI: 10.1093/gastro/goae076.
Explainable AI-prioritized plasma and fecal metabolites in inflammatory bowel disease and their dietary associations.
Onwuka S, Bravo-Merodio L, Gkoutos G, Acharjee A
iScience. 2024; 27(7):110298.
PMID: 39040076
PMC: 11261406.
DOI: 10.1016/j.isci.2024.110298.
Association between Circulating T Cells and the Gut Microbiome in Healthy Individuals: Findings from a Pilot Study.
Vivek S, Shen Y, Guan W, Onyeaghala G, Oyenuga M, Staley C
Int J Mol Sci. 2024; 25(13).
PMID: 38999941
PMC: 11241708.
DOI: 10.3390/ijms25136831.
Untapped potential of gut microbiome for hypertension management.
Gao K, Wang P, Mei X, Yang T, Yu K
Gut Microbes. 2024; 16(1):2356278.
PMID: 38825779
PMC: 11152106.
DOI: 10.1080/19490976.2024.2356278.
An integrative multi-omic analysis defines gut microbiota, mycobiota, and metabolic fingerprints in ulcerative colitis patients.
Scanu M, Toto F, Petito V, Masi L, Fidaleo M, Puca P
Front Cell Infect Microbiol. 2024; 14:1366192.
PMID: 38779566
PMC: 11109417.
DOI: 10.3389/fcimb.2024.1366192.
Novel approaches in IBD therapy: targeting the gut microbiota-bile acid axis.
Pan Y, Zhang H, Li M, He T, Guo S, Zhu L
Gut Microbes. 2024; 16(1):2356284.
PMID: 38769683
PMC: 11110704.
DOI: 10.1080/19490976.2024.2356284.
Association between gut microbiota and autoimmune cholestatic liver disease, a Mendelian randomization study.
Cui Y, Guo Y, Kong Y, Zhang G
Front Microbiol. 2024; 15:1348027.
PMID: 38601930
PMC: 11004368.
DOI: 10.3389/fmicb.2024.1348027.
Systematic review of metabolomic alterations in ulcerative colitis: unveiling key metabolic signatures and pathways.
Liu M, Guo S, Wang L
Therap Adv Gastroenterol. 2024; 17:17562848241239580.
PMID: 38560428
PMC: 10981261.
DOI: 10.1177/17562848241239580.
Integrative Multiomics Profiling Unveils the Protective Function of Ulinastatin against Dextran Sulfate Sodium-Induced Colitis.
Yu T, Yan J, Wang R, Zhang L, Hu X, Xu J
Antioxidants (Basel). 2024; 13(2).
PMID: 38397811
PMC: 10886110.
DOI: 10.3390/antiox13020214.
Mechanism of intestinal microbiota disturbance promoting the occurrence and development of esophageal squamous cell carcinoma--based on microbiomics and metabolomics.
Huang X, Chen X, Wan G, Yang D, Zhu D, Jia L
BMC Cancer. 2024; 24(1):245.
PMID: 38388357
PMC: 10885407.
DOI: 10.1186/s12885-024-11982-8.
Therapeutic applications of gut microbes in cardiometabolic diseases: current state and perspectives.
Yuan L, Li Y, Chen M, Xue L, Wang J, Ding Y
Appl Microbiol Biotechnol. 2024; 108(1):156.
PMID: 38244075
PMC: 10799778.
DOI: 10.1007/s00253-024-13007-7.
Gut microbiota-derived 12-ketolithocholic acid suppresses the IL-17A secretion from colonic group 3 innate lymphoid cells to prevent the acute exacerbation of ulcerative colitis.
Li N, Ma P, Li Y, Shang X, Nan X, Shi L
Gut Microbes. 2023; 15(2):2290315.
PMID: 38062857
PMC: 10730201.
DOI: 10.1080/19490976.2023.2290315.